Clinical trials: Grade 4 Malignant Glioma
Astrocytoma, Grade IV, Glioblastoma
BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
The main purposes of this study are: I. To assess that the four habitats within the tumor (HAT and LAT) and edema (IPE and VPE) in high-grade glioma are different at vascular, tissular, cellular and molecular levels. II.
- Conditions
- Astrocytoma, Grade IV, Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype
- Trial name
- BIOhabitats (NCT05375318)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Juan M Garcia-Gomez
Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion, Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion
Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"
The investigators will look for the presence of the fusion gene in all patients operated on for glioma. This search will be limited to all gliomas that show no IDH1 mutation, the latter being sought in both routine and anomalies…
- Trial name
- TARGET (NCT02824133)
- Testing
- AZD4547
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT01172964
- Testing
- flucytosine, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4)
A Study of 177Lu-PSMA-617 in People With Gliomas
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
- Conditions
- Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered
- Trial name
- NCT07223034
- Testing
- Temozolomide, 177Lu-PSMA-617, 68Ga-PSMA-PET scan/ MRI
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioma, Glioblastoma
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of…
- Conditions
- Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma
- Trial name
- NCT07541781
- Testing
- Sitagliptin, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Kailin Yang, MD, PhD
Glioblastoma Multiforme (WHO Grade IV), Anaplastic Astrocytoma (WHO Grade III)
Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
Cure rates for patients with high grade glioma remain disappointing, in part because tumor cells are often resistant to chemotherapy, and because using higher doses of chemotherapy causes damage to normal blood cells.
- Trial name
- NCT00272870
- Testing
- 06Benzylguanine, MGMT P140K, Meltenyi CliniMacs
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glioblastoma Multiforme, Glioblastoma
Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)
Purposes: The purpose of this phase-II clinical trial is to determine whether or not ADCTA-G, a biologic "vaccine" preparation of patient's own dendritic cell (DC) for glioblastoma multiforme (GBM) treatment, is safe and…
- Trial name
- NCT02772094
- Testing
- Single arm, open-label
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Malignant Glioma, Glioblastoma
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
This is a Phase 1/2 clinical trial to evaluate a new combination of drugs, marizomib (MRZ) and bevacizumab (BEV; Avastin®), for the treatment of WHO Grade IV malignant glioma.
- Trial name
- NCT02330562
- Testing
- MRZ, BEV
- Where
- 5 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Celgene
Grade IV Malignant Glioma
Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma
1. Purpose of the Study - This protocol aims to demonstrate the feasibility and safety of autologous ALD-451 cells administered intravenously in World Health Organization (WHO) grade IV malignant glioma patients following…
- Trial name
- NCT01639612
- Testing
- ALD-451
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Henry Friedman
WHO Grade 3 Glioma, WHO Grade 4 Glioma
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma
This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come…
- Trial name
- NCT06444412
- Testing
- Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Glioblastoma, Malignant Glioma
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma…
- Conditions
- Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme
- Trial name
- ATTAC-P (NCT03615404)
- Testing
- CMV-DCs with GM-CSF, Td (tetanus toxoid)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
- Conditions
- Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Trial name
- NCT06896110
- Testing
- Nivolumab, Azacitidine (AZA), lumbar puncture
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Andrew P. Groves
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Gliosarcoma, Glioblastoma
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Objectives: To determine maximum tolerated dose of farnesyl transferase inhibitor, SCH 66336, when administered w TEMODAR®. To characterize any toxicity associated w combo of farnesyl transferase inhibitor, SCH 66336, \&…
- Conditions
- Gliosarcoma, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT00612651
- Testing
- Temodar and SCH 66336
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Duke University
WHO Grade III Gliomas, WHO Grade IV Gliomas
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
This is a single-center, open-label, multi-dose phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of ZSNeo-DC1.1, a personalized dendritic cell injection, in subjects with recurrent or…
- Trial name
- NCT06253234
- Testing
- personalized dendritic cell injection ZSNeo-DC1.1
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tiantan Hospital
Malignant Glioma, Glioblastoma Multiforme
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.
- Trial name
- NCT02590263
- Testing
- Whole Brain Radiation, Temozolomide, ABT-414
- Where
- 22 sites in Japan
- Volunteers
- 53 people
- Sponsor
- AbbVie
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, Malignant Glioma
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the…
- Trial name
- NCT02903069
- Testing
- MRZ, TMZ, RT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Celgene
Glioblastoma Multiforme, Glioblastoma
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV
- Trial name
- ATTAC-II (NCT02465268)
- Testing
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of Florida
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic